MX2023001049A - Composiciones y métodos para tratar infecciones virales. - Google Patents
Composiciones y métodos para tratar infecciones virales.Info
- Publication number
- MX2023001049A MX2023001049A MX2023001049A MX2023001049A MX2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A MX 2023001049 A MX2023001049 A MX 2023001049A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- nucleic acids
- compositions
- methods
- viral infections
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 1
- 108020004459 Small interfering RNA Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 108091006116 chimeric peptides Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente solicitud proporciona péptidos y ácidos nucleicos que son útiles para tratar la infección por virus (por ejemplo, SARS-CoV-2). Los péptidos ilustrativos comprenden péptidos quiméricos y péptidos de bloqueo que bloquean la interacción entre SPIKE y ACE2. Los ejemplos de ácidos nucleicos incluyen ARNip que se dirigen específicamente al SARS-CoV-2. Las presentes solicitudes también proporcionan complejos y nanopartículas que comprenden además un segundo péptido (por ejemplo, un péptido de penetración celular) que facilita la administración intracelular de los péptidos y ácidos nucleicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2007849 | 2020-07-24 | ||
| PCT/US2021/043077 WO2022020782A1 (en) | 2020-07-24 | 2021-07-23 | Compositions and methods for treating viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001049A true MX2023001049A (es) | 2023-04-11 |
Family
ID=77398656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001049A MX2023001049A (es) | 2020-07-24 | 2021-07-23 | Composiciones y métodos para tratar infecciones virales. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230304010A1 (es) |
| EP (1) | EP4185602A1 (es) |
| JP (1) | JP2023536436A (es) |
| CN (1) | CN116724059A (es) |
| AU (1) | AU2021314336A1 (es) |
| CA (1) | CA3190101A1 (es) |
| MX (1) | MX2023001049A (es) |
| WO (1) | WO2022020782A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113298A1 (en) * | 2003-09-15 | 2005-05-26 | The Brigham And Women's Hospital, Inc. | Receptor binding peptides derived from the SARS S protein |
| US7514530B2 (en) | 2004-04-26 | 2009-04-07 | Centre National De La Recherche Scientifique | Peptide carrier for delivering siRNA into mammalian cells |
| US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2012137036A1 (en) | 2011-04-04 | 2012-10-11 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053881A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053882A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2014053880A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| CA2971643C (en) | 2014-12-24 | 2024-03-12 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of molecules |
| CA3025523A1 (en) * | 2016-05-27 | 2017-11-30 | Aadigen, Llc | Peptides and nanoparticles for intracellular delivery of genome-editing molecules |
| JP2020530463A (ja) * | 2017-08-10 | 2020-10-22 | アーディジェン， エルエルシー | ウイルスの細胞内送達のためのペプチドおよびナノ粒子 |
-
2021
- 2021-07-23 WO PCT/US2021/043077 patent/WO2022020782A1/en active Application Filing
- 2021-07-23 MX MX2023001049A patent/MX2023001049A/es unknown
- 2021-07-23 CA CA3190101A patent/CA3190101A1/en active Pending
- 2021-07-23 JP JP2023504816A patent/JP2023536436A/ja active Pending
- 2021-07-23 CN CN202180062573.5A patent/CN116724059A/zh active Pending
- 2021-07-23 EP EP21756120.8A patent/EP4185602A1/en active Pending
- 2021-07-23 US US18/017,644 patent/US20230304010A1/en active Pending
- 2021-07-23 AU AU2021314336A patent/AU2021314336A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230304010A1 (en) | 2023-09-28 |
| EP4185602A1 (en) | 2023-05-31 |
| WO2022020782A1 (en) | 2022-01-27 |
| JP2023536436A (ja) | 2023-08-25 |
| CA3190101A1 (en) | 2022-01-27 |
| AU2021314336A1 (en) | 2023-03-09 |
| CN116724059A (zh) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007930A (es) | Compuestos moduladores de diacilglicerol quinasa. | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| WO2018136396A3 (en) | Crisprs | |
| PH12018501962A1 (en) | Stablizied soluble pre-fusion rsv f proteins | |
| WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| SG195194A1 (en) | Nanogels | |
| PH12021550822A1 (en) | Compositions and methods for the treatment of viral infections | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| WO2021226555A3 (en) | Chromatin remodelers to enhance targeted gene activation | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| CR20220138A (es) | Composiciones y métodos para el tratamiento de infecciones virales | |
| WO2019210267A3 (en) | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same | |
| WO2020252393A8 (en) | Compositions and methods for the treatment of human immunodeficiency virus | |
| MX2017016227A (es) | Peptidos anti-infecciosos de amplio espectro. | |
| WO2009120339A3 (en) | Vectors for delivering disease neutralizing agents | |
| MX2023001049A (es) | Composiciones y métodos para tratar infecciones virales. | |
| MX2019015143A (es) | Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso. | |
| MX2018000023A (es) | Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina. | |
| MX2009005026A (es) | Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. | |
| PH12018500468A1 (en) | Fusion protein | |
| MX2022002417A (es) | Virus vaccinia oncoliticos modificados geneticamente y metodos de uso de los mismos. | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| WO2021061707A8 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| WO2021046398A3 (en) | Combination antiviral therapy for measles | |
| MX2021013698A (es) | Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb). |